Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy

Results from a monoinstitutional cohort analysis of long-term survivors

Vitaliana De Sanctis, Marco Alfò, Alice Di Rocco, Michela Ansuinelli, Eleonora Russo, Mattia F. Osti, Maurizio Valeriani, Giuseppe Minniti, Lavinia Grapulin, Daniela Musio, Stefano Bracci, Alessandra Spagnoli, Maria Luisa Moleti, Vincenzo Tombolini, Maurizio Martelli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3.75%) with cumulative incidence of 3.47% at 15 years and 11% at 17 years, with a 17-year second cancer-free survival of 82%. We observed 2 papillary thyroid cancers with a standardized incidence ratio (SIR) of 7.97 and an absolute excess risk (AER) of 17. 84 and 1 acute myeloid leukemia (AML) with an SIR of 66.53 and an AER of 10.05. No breast cancer occurred. Although we should take into account the limits of the proposed statistical analysis, combined modality treatment was related to a significant SIR and AER for thyroid cancer and acute myeloid leukemia.

Original languageEnglish
Pages (from-to)554-560
Number of pages7
JournalHematological Oncology
Volume35
Issue number4
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Second Primary Neoplasms
Leucovorin
Bleomycin
Vincristine
B-Cell Lymphoma
Prednisone
Methotrexate
Doxorubicin
Cyclophosphamide
Survivors
Cohort Studies
Radiotherapy
Incidence
Acute Myeloid Leukemia
Survival
Thyroid Neoplasms
Rituximab
Breast Neoplasms

Keywords

  • lymphoma
  • myeloid leukemias
  • radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy : Results from a monoinstitutional cohort analysis of long-term survivors. / De Sanctis, Vitaliana; Alfò, Marco; Di Rocco, Alice; Ansuinelli, Michela; Russo, Eleonora; Osti, Mattia F.; Valeriani, Maurizio; Minniti, Giuseppe; Grapulin, Lavinia; Musio, Daniela; Bracci, Stefano; Spagnoli, Alessandra; Moleti, Maria Luisa; Tombolini, Vincenzo; Martelli, Maurizio.

In: Hematological Oncology, Vol. 35, No. 4, 01.12.2017, p. 554-560.

Research output: Contribution to journalArticle

De Sanctis, Vitaliana ; Alfò, Marco ; Di Rocco, Alice ; Ansuinelli, Michela ; Russo, Eleonora ; Osti, Mattia F. ; Valeriani, Maurizio ; Minniti, Giuseppe ; Grapulin, Lavinia ; Musio, Daniela ; Bracci, Stefano ; Spagnoli, Alessandra ; Moleti, Maria Luisa ; Tombolini, Vincenzo ; Martelli, Maurizio. / Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy : Results from a monoinstitutional cohort analysis of long-term survivors. In: Hematological Oncology. 2017 ; Vol. 35, No. 4. pp. 554-560.
@article{1af21c63637643db9f7f423a2e371297,
title = "Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors",
abstract = "Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3.75{\%}) with cumulative incidence of 3.47{\%} at 15 years and 11{\%} at 17 years, with a 17-year second cancer-free survival of 82{\%}. We observed 2 papillary thyroid cancers with a standardized incidence ratio (SIR) of 7.97 and an absolute excess risk (AER) of 17. 84 and 1 acute myeloid leukemia (AML) with an SIR of 66.53 and an AER of 10.05. No breast cancer occurred. Although we should take into account the limits of the proposed statistical analysis, combined modality treatment was related to a significant SIR and AER for thyroid cancer and acute myeloid leukemia.",
keywords = "lymphoma, myeloid leukemias, radiotherapy",
author = "{De Sanctis}, Vitaliana and Marco Alf{\`o} and {Di Rocco}, Alice and Michela Ansuinelli and Eleonora Russo and Osti, {Mattia F.} and Maurizio Valeriani and Giuseppe Minniti and Lavinia Grapulin and Daniela Musio and Stefano Bracci and Alessandra Spagnoli and Moleti, {Maria Luisa} and Vincenzo Tombolini and Maurizio Martelli",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/hon.2377",
language = "English",
volume = "35",
pages = "554--560",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "4",

}

TY - JOUR

T1 - Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy

T2 - Results from a monoinstitutional cohort analysis of long-term survivors

AU - De Sanctis, Vitaliana

AU - Alfò, Marco

AU - Di Rocco, Alice

AU - Ansuinelli, Michela

AU - Russo, Eleonora

AU - Osti, Mattia F.

AU - Valeriani, Maurizio

AU - Minniti, Giuseppe

AU - Grapulin, Lavinia

AU - Musio, Daniela

AU - Bracci, Stefano

AU - Spagnoli, Alessandra

AU - Moleti, Maria Luisa

AU - Tombolini, Vincenzo

AU - Martelli, Maurizio

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3.75%) with cumulative incidence of 3.47% at 15 years and 11% at 17 years, with a 17-year second cancer-free survival of 82%. We observed 2 papillary thyroid cancers with a standardized incidence ratio (SIR) of 7.97 and an absolute excess risk (AER) of 17. 84 and 1 acute myeloid leukemia (AML) with an SIR of 66.53 and an AER of 10.05. No breast cancer occurred. Although we should take into account the limits of the proposed statistical analysis, combined modality treatment was related to a significant SIR and AER for thyroid cancer and acute myeloid leukemia.

AB - Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3.75%) with cumulative incidence of 3.47% at 15 years and 11% at 17 years, with a 17-year second cancer-free survival of 82%. We observed 2 papillary thyroid cancers with a standardized incidence ratio (SIR) of 7.97 and an absolute excess risk (AER) of 17. 84 and 1 acute myeloid leukemia (AML) with an SIR of 66.53 and an AER of 10.05. No breast cancer occurred. Although we should take into account the limits of the proposed statistical analysis, combined modality treatment was related to a significant SIR and AER for thyroid cancer and acute myeloid leukemia.

KW - lymphoma

KW - myeloid leukemias

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85010775214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010775214&partnerID=8YFLogxK

U2 - 10.1002/hon.2377

DO - 10.1002/hon.2377

M3 - Article

VL - 35

SP - 554

EP - 560

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -